Clinical Trial Update: GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (GENERATION HD2) is evaluating safety, biomarkers, and efficacy of tominersen versus placebo in participants with prodromal and early H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Tominersen (tominersen)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Huntington Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING